NASDAQ · PSTX
Healthcare · Biotechnology
$9.50
Up+$0.00 (+0.00%)
Updated Aug 28, 2026, 1:06 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PSTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning PSTX.
PSTX research
Company profile and research snapshot.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 26, 2024 | BTIG | Neutral | — |
| Nov 26, 2024 | William Blair | Market Perform | — |
| Nov 26, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jan 8, 2025
Roche has completed the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company, through a tender offer and subsequent merger. Poseida's pipeline includes investigational allogeneic CAR-T cell therapies and in vivo genetic medicines.
GlobeNewswire Inc. · Dec 9, 2024
Roche has commenced a tender offer to acquire all outstanding shares of Poseida Therapeutics for $9.00 per share in cash, plus a contingent value right of up to $4.00 per share. The transaction is subject to customary closing conditions and regulatory approvals.
GlobeNewswire Inc. · Nov 27, 2024
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed mergers of Poseida Therapeutics, Zuora, and Manitex International.
Zacks Investment Research · May 13, 2024
Akoya (AKYA) delivered earnings and revenue surprises of -16.67% and 23.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PSTX.
No results
No recent SID articles mention PSTX.
